229 related articles for article (PubMed ID: 14583762)
1. Second primary malignancies in thyroid cancer patients.
Rubino C; de Vathaire F; Dottorini ME; Hall P; Schvartz C; Couette JE; Dondon MG; Abbas MT; Langlois C; Schlumberger M
Br J Cancer; 2003 Nov; 89(9):1638-44. PubMed ID: 14583762
[TBL] [Abstract][Full Text] [Related]
2. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study.
Piscopo L; Volpe F; Nappi C; Zampella E; Manganelli M; Matrisciano F; Totaro P; Pace L; Maurea S; Cuocolo A; Klain M
Curr Oncol; 2022 Dec; 30(1):37-44. PubMed ID: 36661652
[TBL] [Abstract][Full Text] [Related]
3. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
Reinecke MJ; Ahlers G; Burchert A; Eilsberger F; Flux GD; Marlowe RJ; Mueller HH; Reiners C; Rohde F; van Santen HM; Luster M
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment.
Tran TV; Rubino C; Allodji R; Andruccioli M; Bardet S; Diallo I; Dottorini M; Garsi J; Hall P; Henry-Amar M; Lamart S; Le Thai F; Lönn S; Ricard M; Schvartz C; Schlumberger M; Journy N; de Vathaire F
Br J Cancer; 2022 Dec; 127(12):2118-2124. PubMed ID: 36224404
[TBL] [Abstract][Full Text] [Related]
5. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
[TBL] [Abstract][Full Text] [Related]
6. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer.
Brown AP; Chen J; Hitchcock YJ; Szabo A; Shrieve DC; Tward JD
J Clin Endocrinol Metab; 2008 Feb; 93(2):504-15. PubMed ID: 18029468
[TBL] [Abstract][Full Text] [Related]
7. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
8. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
Durante C; Haddy N; Baudin E; Leboulleux S; Hartl D; Travagli JP; Caillou B; Ricard M; Lumbroso JD; De Vathaire F; Schlumberger M
J Clin Endocrinol Metab; 2006 Aug; 91(8):2892-9. PubMed ID: 16684830
[TBL] [Abstract][Full Text] [Related]
10. Second primary cancers in thyroid cancer patients: a multinational record linkage study.
Sandeep TC; Strachan MW; Reynolds RM; Brewster DH; Scélo G; Pukkala E; Hemminki K; Anderson A; Tracey E; Friis S; McBride ML; Kee-Seng C; Pompe-Kirn V; Kliewer EV; Tonita JM; Jonasson JG; Martos C; Boffetta P; Brennan P
J Clin Endocrinol Metab; 2006 May; 91(5):1819-25. PubMed ID: 16478820
[TBL] [Abstract][Full Text] [Related]
11. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
[TBL] [Abstract][Full Text] [Related]
12. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis.
Subramanian S; Goldstein DP; Parlea L; Thabane L; Ezzat S; Ibrahim-Zada I; Straus S; Brierley JD; Tsang RW; Gafni A; Rotstein L; Sawka AM
Thyroid; 2007 Dec; 17(12):1277-88. PubMed ID: 18020916
[TBL] [Abstract][Full Text] [Related]
13. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
15. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review.
Clement SC; Peeters RP; Ronckers CM; Links TP; van den Heuvel-Eibrink MM; Nieveen van Dijkum EJ; van Rijn RR; van der Pal HJ; Neggers SJ; Kremer LC; van Eck-Smit BL; van Santen HM
Cancer Treat Rev; 2015 Dec; 41(10):925-34. PubMed ID: 26421813
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors.
Sawka AM; Lea J; Alshehri B; Straus S; Tsang RW; Brierley JD; Thabane L; Rotstein L; Gafni A; Ezzat S; Goldstein DP
Clin Endocrinol (Oxf); 2008 Apr; 68(4):610-7. PubMed ID: 17973944
[TBL] [Abstract][Full Text] [Related]
17. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Haugen BR; Alexander EK; Bible KC; Doherty GM; Mandel SJ; Nikiforov YE; Pacini F; Randolph GW; Sawka AM; Schlumberger M; Schuff KG; Sherman SI; Sosa JA; Steward DL; Tuttle RM; Wartofsky L
Thyroid; 2016 Jan; 26(1):1-133. PubMed ID: 26462967
[TBL] [Abstract][Full Text] [Related]
18. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
19. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group.
Ron E; Doody MM; Becker DV; Brill AB; Curtis RE; Goldman MB; Harris BS; Hoffman DA; McConahey WM; Maxon HR; Preston-Martin S; Warshauer ME; Wong FL; Boice JD
JAMA; 1998 Jul 22-29; 280(4):347-55. PubMed ID: 9686552
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer.
Yu CY; Saeed O; Goldberg AS; Farooq S; Fazelzad R; Goldstein DP; Tsang RW; Brierley JD; Ezzat S; Thabane L; Goldsmith CH; Sawka AM
Thyroid; 2018 Dec; 28(12):1662-1673. PubMed ID: 30370820
[No Abstract] [Full Text] [Related]
[Next] [New Search]
